Long-term modeling on HPV vaccination: do we really need any more?

摘要: The human papillomavirus (HPV) is closely related to cervical cancer. In 2007, the EMA approved two vaccines, a bivalent and quadrivalent one, launched at three-dose schedules very high prices worldwide. We describe what happened in EU might change near future from an economic perspective. HPV vaccination now established most countries. main target group of programs girls aged 10–14 years. Many western countries used competitive tendering purchase achieving considerable savings. extension males has been hotly debated issue. sex limitation implies that this cannot by definition achieve ‘herd immunity’ effect. recently two-dose schedule for both vaccines should lead savings, although it hard predict how forthcoming nonavalent vaccine will affect market situation. Several evaluations based on long-term models have published recent years...